BR0205774A - Adjuvant system for antibody production, vaccine and use - Google Patents
Adjuvant system for antibody production, vaccine and useInfo
- Publication number
- BR0205774A BR0205774A BR0205774A BR0205774A BR0205774A BR 0205774 A BR0205774 A BR 0205774A BR 0205774 A BR0205774 A BR 0205774A BR 0205774 A BR0205774 A BR 0205774A BR 0205774 A BR0205774 A BR 0205774A
- Authority
- BR
- Brazil
- Prior art keywords
- proposed product
- peptic
- antibodies
- protein
- poison
- Prior art date
Links
- 239000002671 adjuvant Substances 0.000 title abstract 2
- 230000016784 immunoglobulin production Effects 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title 1
- 239000000463 material Substances 0.000 abstract 5
- 230000001175 peptic effect Effects 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 231100000636 lethal dose Toxicity 0.000 abstract 2
- 231100000614 poison Toxicity 0.000 abstract 2
- 239000002574 poison Substances 0.000 abstract 2
- 230000001681 protective effect Effects 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 210000004907 gland Anatomy 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 229960001438 immunostimulant agent Drugs 0.000 abstract 1
- 239000003022 immunostimulating agent Substances 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- -1 polyoxyethylene Polymers 0.000 abstract 1
- 239000013014 purified material Substances 0.000 abstract 1
- 239000003998 snake venom Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/38—Antigens from snakes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
"SISTEMA ADJUVANTE PARA PRODUçãO DE ANTICORPOS". Caracteriza-se por ser um produto para ser usado na geração de anticorpos altamente eficientes na proteção contra material protéico ou péptico que consiste na administração de hospedeiro não-humano de uma composição constituída pelo material protéico ou péptico encapsulado em liposomas constituídos por polioxietileno 2-cetil éter, dicetil fosfato e colesterol e dessa forma dando proteção ao próprio animal ou permitindo a retirada de células sensibilizadas ou anticorpos ditos contra o material protéico ou péptico. O produto proposto foi testado utilizando-se material protéico extraído da glândula venenífera de serpentes ou este material purificado. O produto proposto se mostra eficiente na produção de anticorpos protetores empregando doses pequenas (abaixo de 10 <109>g / camundongo) do material encapsulado na imunização de animais experimentais. O produto proposto comparado nas mesmas condições a adjuvantes tradicionais, apresenta a mesma eficácia com relação a produção de anticorpos protetores contra desafios com doses letais do veneno. Apresenta um custo financeiro inferior e baixa toxicidade. O produto proposta permite a associação com imunoestimulantes aumentando a intensidade de proteção contra desafios com doses letais de veneno."ASSISTANT ANTIBODY PRODUCTION SYSTEM". It is a product for use in the generation of antibodies that are highly efficient in protecting against protein or peptic material consisting of the non-human host administration of a composition consisting of protein or peptic material encapsulated in liposomes consisting of 2-cetyl polyoxyethylene. ether, diketyl phosphate and cholesterol and thereby providing protection for the animal itself or allowing for the removal of sensitized cells or antibodies said against the protein or peptic material. The proposed product was tested using proteinaceous material extracted from the snake venom gland or this purified material. The proposed product proves to be efficient in producing protective antibodies by employing small doses (below 10 µg / mouse) of the encapsulated material in the immunization of experimental animals. The proposed product compared under the same conditions to traditional adjuvants, has the same efficacy with respect to the production of protective antibodies against challenges with lethal doses of poison. It has a lower financial cost and low toxicity. The proposed product allows the association with immunostimulants increasing the intensity of protection against challenges with lethal doses of poison.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR0205774A BR0205774A (en) | 2002-02-27 | 2002-02-27 | Adjuvant system for antibody production, vaccine and use |
| PCT/BR2003/000025 WO2003072132A1 (en) | 2002-02-27 | 2003-02-27 | Adjuvant system for the production of antibodies, vaccine and use |
| AU2003209869A AU2003209869A1 (en) | 2002-02-27 | 2003-02-27 | Adjuvant system for the production of antibodies, vaccine and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR0205774A BR0205774A (en) | 2002-02-27 | 2002-02-27 | Adjuvant system for antibody production, vaccine and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0205774A true BR0205774A (en) | 2004-04-20 |
Family
ID=27761951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0205774A BR0205774A (en) | 2002-02-27 | 2002-02-27 | Adjuvant system for antibody production, vaccine and use |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2003209869A1 (en) |
| BR (1) | BR0205774A (en) |
| WO (1) | WO2003072132A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4102996A (en) * | 1977-04-20 | 1978-07-25 | Merck & Co., Inc. | Method of preparing hepatitis B core antigen |
| DE3308458A1 (en) * | 1983-03-10 | 1984-09-13 | Behringwerke Ag, 3550 Marburg | METHOD FOR ADJUVING VACCINES |
| US5023086A (en) * | 1987-03-13 | 1991-06-11 | Micro-Pak, Inc. | Encapsulated ionophore growth factors |
| JPH05201877A (en) * | 1992-01-30 | 1993-08-10 | Kanebo Ltd | Adjuvant composition |
-
2002
- 2002-02-27 BR BR0205774A patent/BR0205774A/en not_active Application Discontinuation
-
2003
- 2003-02-27 WO PCT/BR2003/000025 patent/WO2003072132A1/en not_active Ceased
- 2003-02-27 AU AU2003209869A patent/AU2003209869A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003072132A1 (en) | 2003-09-04 |
| AU2003209869A1 (en) | 2003-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122869T1 (en) | POLYPEPTIDE VACCINES FOR BROAD PROTECTION AGAINST HIGHLY INFECTIOUS MENINGITIDOCOCCAL LINEAGES | |
| RU2434638C2 (en) | Vaccine of c perfringens alpha toxoid | |
| Diaz et al. | Parasite molecules and host responses in cystic echinococcosis | |
| NO20082472L (en) | Vaccine compositions comprising a saponin adjuvant | |
| ATE287947T1 (en) | ORAL IMMUNIZATION BY USING TRANSGENIC PLANTS | |
| ES2142874T3 (en) | PREPARATION OF ANTIGENS AND VACCINES OF VIRUSES OF THE MYSTERIOUS DISEASE, ANTIGENS AND VACCINES OBTAINED FOR THE PREVENTION OF THIS DISEASE. | |
| ATE301470T1 (en) | VACCINATE FORMULATION CONTAINING SUGAR ALCOHOL AND LOW CONCENTRATIONS OF INORGANIC IONS | |
| BR0113112A (en) | Antibodies, antidual integrin, compositions, methods and uses | |
| BR0008188A (en) | Growth differentiation factor inhibitors and uses for them | |
| PT714444E (en) | ATENUATION OF AN IMMUNODOMINANT EPITOPO OF AN ANTIGEN FOR USE IN VACCINES AND IMMUNOTHERAPIES FOR PLANTS, ANIMALS AND MEN | |
| BR9510223A (en) | Adjuvant for vaccines use of a lipid polysaccharide process to prepare an emulsion and vaccine cacina | |
| DE69637481D1 (en) | Human antibodies to IL-8 derived from immunized Xenomae | |
| Tsuji et al. | Recombinant Ascaris 16-Kilodalton protein-induced protection against Ascaris suum larval migration after intranasal vaccination in pigs | |
| ES2195169T3 (en) | VACCINES AGAINST CALMIDIES AND IMMUNOGENIC COMPOSITIONS CONTAINING AN EXTERNAL MEMBRANE ANTIGEN AND METHODS FOR PREPARATION. | |
| CY1107188T1 (en) | E. coli avian vaccine for anti-colic protection | |
| Jones et al. | Protollin™: a novel adjuvant for intranasal vaccines | |
| Dutta et al. | Immunogenicity and protective potential of a Plasmodium spp. enolase peptide displayed on archaeal gas vesicle nanoparticles | |
| Rajapakse et al. | 1, 25-Dihydroxyvitamin D3 induces splenocyte apoptosis and enhances BALB/c mice sensitivity to toxoplasmosis | |
| BR0205774A (en) | Adjuvant system for antibody production, vaccine and use | |
| Pérez et al. | Proteliposome-derived Cochleate as an immunomodulator for nasal vaccine | |
| BR9710849A (en) | Vaccine containing a peroxy-redoxin and / or a beta-tubulin. | |
| PT1021196E (en) | USE OF A CHEMICALLY STABILIZED CHLORIDE SOLUTION TO INHIBIT AN IMMUNITY RESPONSE SPECIFIC TO ANTIGEN | |
| DE69633919D1 (en) | MULTIPURPOSE VACCINE AGAINST ENVIRONED VIRUSES | |
| AR035489A1 (en) | 4-Phenyl-1- (1-Phenyl-Cyclohexyl) -1,2,3,6, -TETRAHYDROPIRIDINES REPLACED, PROCEDURES FOR THEIR PREPARATION, MEDICATIONS CONTAINING THESE COMPOUNDS AND THE USE OF THESE SUBSTANCES FOR THE PREPARATION OF MEDICINES | |
| Singh et al. | Assessment of free radicals and reactive oxygen species milieu in nanoparticles adjuvanted outer membrane proteins vaccine against Salmonella typhi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 4A ANUIDADE(S). |
|
| B08H | Application fees: decision cancelled |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010. |
|
| B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 11A ANUIDADES |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2189 DE 18/12/2012. |
|
| B08H | Application fees: decision cancelled |
Free format text: REFERENTE AOS DESPACHOS PUBLICADOS NA RPI 2189 DE 18/12/2012 E RPI 2222 DE 06/08/2013 |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
| B07E | Notice of approval relating to section 229 industrial property law | ||
| B06A | Notification to applicant to reply to the report for non-patentability or inadequacy of the application according art. 36 industrial patent law | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |